For more information on Nemaura Medical, contact RedChip specialists at: 1-800-REDCHIP (733-2447)
Company Overview
Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices, coupled with artificial intelligence capabilities for digital healthcare. The company’s first product, which is CE approved and undergoing commercial launch, is the sugarBEAT® non-invasive continuous glucose monitoring device and BEAT®diabetes digital healthcare platform. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which help people with Type 1 or Type 2 diabetes and prediabetes respectively to better manage, reverse and prevent the onset of diabetes. BEAT®diabetes is a health subscription service providing 1-on-1 lifestyle coaching and behavior change recommendations driven by personalized data provided by sugarBEAT®. Insulin users can also adjunctively use sugarBEAT® for insulin dosage purposes when calibrated by a finger stick reading. sugarBEAT® is intended to be worn during waking hours and consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals.
The global total addressable market for CGM is estimated at $150 billion per annum. Healthcare costs for persons with type 2 diabetes costs approx. 2.5x as much as a person without diabetes. Employers and healthcare insurers are therefore resorting to programs that will provide long-term sustainable results in stemming the onset of diabetes and, where possible, reversing type 2 diabetes. Nemaura’s solution, which has both a cost and user-friendliness advantage, addresses this increasing demand. CGMs currently have low adoption rates amongst insulin users (negligible use amongst non-insulin users) but is growing rapidly. The U.S. is the largest market with estimated 2.6% (630,000 users) penetration of diagnosed diabetic market (34.2M), representing annual growth of 117% over 2017 (290,000 users). Given sugarBEAT® is non-invasive, affordable and flexible, it is expected to have wider appeal to non-insulin using diabetics, prediabetics and a section of insulin users who dislike competitor CGMs (Abbott, Dexcom and Senseonics) due to their invasiveness, higher cost and inflexibility.
Investment Highlights
sugarBEAT® commercially launched in UK; near-term European launch
CE approved in May 2019; manufacturer scale-up and commercial sales of sugarBEAT® in Germany and the UK underway
200K sensors ordered by licensee following soft launch success
PO forecast for approx. 100K sensors monthly over next two years
FDA application submitted
Disrupting the multi-billion-dollar glucose trending and diabetes management space
sugarBEAT® is a flexible CGM which can be worn for a single day at a time, with no commitment to wear the device continuously for 10 -14 days as is the case with other CGMs, making it unlikely that the daily cost-of-use can be matched by competitors
sugarBEAT® empowers glucose trend data over the course of the day, with measurements recorded every 5 minutes; replaces multiple daily point-in-time finger-stick measurements
Attractive economics
Lowest COGS per CGM patch in the industry
Recurring high-margin revenue model
Upcoming R&D pipeline
Launching continuous lactate monitoring (CLM) near term; $60B+ market
Four additional products in development using BEAT platform, including non-invasive alcohol monitoring (CAM)
Proven and experienced management team
Dr. Faz Chowdhury, CEO - Sole inventor on 50+ granted and pending patents across 15+tech platforms within the medical device and pharma sectors
The global total addressable market for CGM is estimated at $150 billion per annum. Healthcare costs for persons with type 2 diabetes costs approx. 2.5x as much as a person without diabetes. Employers and healthcare insurers are therefore resorting to programs that will provide long-term sustainable results in stemming the onset of diabetes and, where possible, reversing type 2 diabetes. Nemaura’s solution, which has both a cost and user-friendliness advantage, addresses this increasing demand. CGMs currently have low adoption rates amongst insulin users (negligible use amongst non-insulin users) but is growing rapidly. The U.S. is the largest market with estimated 2.6% (630,000 users) penetration of diagnosed diabetic market (34.2M), representing annual growth of 117% over 2017 (290,000 users). Given sugarBEAT® is non-invasive, affordable and flexible, it is expected to have wider appeal to non-insulin using diabetics, prediabetics and a section of insulin users who dislike competitor CGMs (Abbott, Dexcom and Senseonics) due to their invasiveness, higher cost and inflexibility.
Investment Highlights
sugarBEAT® commercially launched in UK; near-term European launch
CE approved in May 2019; manufacturer scale-up and commercial sales of sugarBEAT® in Germany and the UK underway
200K sensors ordered by licensee following soft launch success
PO forecast for approx. 100K sensors monthly over next two years
FDA application submitted
Disrupting the multi-billion-dollar glucose trending and diabetes management space
sugarBEAT® is a flexible CGM which can be worn for a single day at a time, with no commitment to wear the device continuously for 10 -14 days as is the case with other CGMs, making it unlikely that the daily cost-of-use can be matched by competitors
sugarBEAT® empowers glucose trend data over the course of the day, with measurements recorded every 5 minutes; replaces multiple daily point-in-time finger-stick measurements
Attractive economics
Lowest COGS per CGM patch in the industry
Recurring high-margin revenue model
Upcoming R&D pipeline
Launching continuous lactate monitoring (CLM) near term; $60B+ market
Four additional products in development using BEAT platform, including non-invasive alcohol monitoring (CAM)
Proven and experienced management team
Dr. Faz Chowdhury, CEO - Sole inventor on 50+ granted and pending patents across 15+tech platforms within the medical device and pharma sectors
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at
www.sec.gov.
Nemaura Medical (NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee of $6,000 and 15,000 shares of Rule 144 stock for three months of investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.
